Karanikas, Chrisanthi A.
Eli Lilly (United States)
4 papers on CoChatORCID 0009-0008-0614-8264
Most cited papers
- Verified
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 1,080
- Verified
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Hartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care
Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management
Cited by 351
- Verified
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., et al. (2023) · Diabetes Care
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 208
- Verified
Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
Cusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine
Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment
Cited by 89
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free